Roche files Actemra for prevention of joint damage in US
This article was originally published in Scrip
Genentech (Roche) has submitted a supplemental BLA to the US FDA for its first-in-class interleukin-6 inhibitor Actemra (tocilizumab) for an indication of prevention of structural joint damage and improvement of physical function in adults with moderately to severely active rheumatoid arthritis (RA).
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.